GBA相关帕金森病中β-葡萄糖脑苷脂酶活性:突变类型至关重要
该研究基于哈佛生物标志物研究和NIH帕金森病生物标志物项目共481名参与者,分析GBA突变类型与帕金森病患者血β-葡萄糖脑苷脂酶活性的横断面和纵向关系。结果显示GBA-PD患者酶活性低于健康对照和特发性PD患者,且残余酶活性与突变严重程度呈负线性相关,纵向随访中突变越严重酶活性下降越快。
要点
- GBA-PD患者血β-葡萄糖脑苷脂酶活性低于健康对照和特发性PD患者。
- 残余酶活性与GBA突变严重程度呈负线性相关,每增加一个严重等级平均降低0.85 μmol/L/h。
- 纵向随访中突变严重程度越高,酶活性下降越快。
核心结论
- 血中残余β-葡萄糖脑苷脂酶活性与帕金森病患者GBA突变的临床严重类型呈负相关。
- β-葡萄糖脑苷脂酶活性是可无创监测并作为治疗靶点的定量内表型。
研究设计与样本
- 横断面和纵向病例对照研究,纳入哈佛生物标志物研究(HBS)和NIH帕金森病生物标志物项目(PDBP)共481名参与者。
- 参与者包括47例携带GBA变异的PD患者(GBA-PD)、247例无GBA变异的特发性PD患者和187名健康对照。
- 纵向分析纳入195名参与者,中位随访2.0年(四分位距1-2年),共548次纵向测量。
主要发现
- 在HBS中,GBA-PD患者血β-葡萄糖脑苷脂酶活性分别低于健康对照和特发性PD患者(p < 0.001)。
- 在PDBP中,GBA-PD患者血β-葡萄糖脑苷脂酶活性分别低于健康对照和特发性PD患者(p < 0.05)。
- 特发性PD患者酶活性无变化。
- 酶定量性状基因座(xQTL)分析显示残余β-葡萄糖脑苷脂酶活性与突变类型呈负线性关联(p < 0.0001)。
- 突变类型严重程度每增加一级,平均β-葡萄糖脑苷脂酶活性预测降低0.85 μmol/L/h(95%置信区间,-1.17,-0.54)。
临床怎么用
- 血β-葡萄糖脑苷脂酶活性可作为GBA-PD患者的无创监测指标,辅助评估突变严重程度相关的酶活性下降。
- 该酶活性是潜在的治疗靶点,可用于患者分层和疗效监测。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To test the relationship between clinically relevant types of GBA mutations (none, risk variants, mild mutations, severe mutations) and β-glucocerebrosidase activity in patients with Parkinson disease (PD) in cross-sectional and longitudinal case-control studies. METHODS: A total of 481 participants from the Harvard Biomarkers Study (HBS) and the NIH Parkinson's Disease Biomarkers Program (PDBP) were analyzed, including 47 patients with PD carrying GBA variants (GBA-PD), 247 without a GBA variant (idiopathic PD), and 187 healthy controls. Longitudinal analysis comprised 195 participants with 548 longitudinal measurements over a median follow-up period of 2.0 years (interquartile range, 1-2 years). RESULTS: β-Glucocerebrosidase activity was low in blood of patients with GBA-PD compared to healthy controls and patients with idiopathic PD, respectively, in HBS (p < 0.001) and PDBP (p < 0.05) in multivariate analyses adjusting for age, sex, blood storage time, and batch. Enzyme activity in patients with idiopathic PD was unchanged. Innovative enzymatic quantitative trait locus (xQTL) analysis revealed a negative linear association between residual β-glucocerebrosidase activity and mutation type with p < 0.0001. For each increment in the severity of mutation type, a reduction of mean β-glucocerebrosidase activity by 0.85 μmol/L/h (95% confidence interval, -1.17, -0.54) was predicted. In a first longitudinal analysis, increasing mutation severity types were prospectively associated with steeper declines in β-glucocerebrosidase activity during a median 2 years of follow-up (p = 0.02). CONCLUSIONS: Residual activity of the β-glucocerebrosidase enzyme measured in blood inversely correlates with clinical severity types of GBA mutations in PD. β-Glucocerebrosidase activity is a quantitative endophenotype that can be monitored noninvasively and targeted therapeutically.
引用
- Huh YE, Chiang MSR, Locascio JJ, et al. β-Glucocerebrosidase activity in GBA-linked Parkinson disease: The type of mutation matters. Neurology. 2020. PMID: 32540937. doi:10.1212/WNL.0000000000009989
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。